Back to my company list

SOM Biotech

The AI engine Fit Assessment

Beta

SOM Biotech leverages machine learning for drug discovery, identifies new patterns for therapeutic development, and actively engages in drug repurposing for orphan diseases.

Blurb

Drug innovation company based on a pioneering AI-based drug discovery technology, that has built a robust pipeline for Orphan CNS diseases.

HQ Location

Spain

Founded

2009

Employees

11 - 50

Total funding raised

$9.99M

Last Funding Event

Venture - Series Unknown, January 1, 2021

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing

Developer of drugs designed for the treatment of rare and critical diseases. The company's artificial intelligence-based drug discovery technology allows for reducing costs and time for drug development, providing a high level of success and reliable patent protection, and engages in the development of candidates, drug pipelines, and compounds to treat diseases, enabling the medical community to optimally combat acute and life-threatening diseases while maintaining safety and tolerance standards.